A Single-center, Prospective, Single-arm Clinical Research Protocol for the Treatment of Pouchitis With Aeromonas sp. MTB Bacteriophage

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT07878026

Title field or adapter rule

{'original_value': 'A Single-center, Prospective, Single-arm Clinical Research Protocol for the Treatment of Pouchitis With Aeromonas sp. MTB Bacteriophage', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:36.586530+00:00

Published At

2026-10-22T00:00:00+00:00

Record Updated At

2026-10-22

Source Retrieved At

2026-10-31T22:18:58.295941+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Pouchitis", "UC - Ulcerative Colitis"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-22", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT07878026"

protocolSection.identificationModule.officialTitle

"A Single-center, Prospective, Single-arm Clinical Research Protocol for the Treatment of Pouchitis With Aeromonas sp. MTB Bacteriophage"

protocolSection.statusModule.overallStatus

"NOT_YET_RECRUITING"

protocolSection.designModule.phases

["EARLY_PHASE1"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Pouchitis (protocolSection.conditionsModule.conditions)
• UC - Ulcerative Colitis (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Pouchitis'], 'description': 'Aeromonas nov. subsp. macrophage-toxic bacteria (MTB) is a newly-identified enteropathogen associated with ulcerative colitis (UC). It secretes aerolysin to specifically damage colonic macrophages. MTB phage is a bacteriophage targeting this pathogen, which can safely and efficiently eliminate MTB in animal models.\n\nTreatment regimen: One bottle per dose, once daily, taken half an hour after meals for two weeks. Patient symptoms shall be assessed after each treatment session.', 'name': 'MTB-targeted phage therapy', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.